APA (7th ed.) Citation

A, S., H, I., H, K., T, T., & Y, H. (2026). Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Interstitial Lung Disease, Induced by Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Carcinoma. IJU case reports, 9(2), e70148. https://doi.org/10.1002/iju5.70148

Chicago Style (17th ed.) Citation

A, Saito, Ishihara H, Kondo H, Takagi T, and Hashimoto Y. "Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Interstitial Lung Disease, Induced by Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Carcinoma." IJU Case Reports 9, no. 2 (2026): e70148. https://doi.org/10.1002/iju5.70148.

MLA (9th ed.) Citation

A, Saito, et al. "Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Interstitial Lung Disease, Induced by Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Carcinoma." IJU Case Reports, vol. 9, no. 2, 2026, p. e70148, https://doi.org/10.1002/iju5.70148.